According to FutureWise analysis, the market for Antibody Drug Conjugate is expected to reach US$ 26.68 billion by 2031 at a CAGR of 16.6% over the forecast period of 2023-2031.
Antibody-drug conjugates (ADCs) are highly targeted biopharmaceutical medications that combine monoclonal antibodies to recognize surface antigens-specific tumor cells with highly potent anti-cancer agents linked via a chemical linker. Antibody-drug conjugates are complex molecules that require careful attention to various components. The selection of an appropriate target, a mAb, cytotoxic payload, and how the antibody is linked to the load are critical determinants of the safety and effectiveness of ADCs. These targeted agents combine antibodies' unique and very sensitive targeting capabilities, allowing acute discrimination between healthy and cancerous tissues with the cell-killing ability of cytotoxic drugs.
Antibodies are glycoproteins generated by the body in response to foreign particles. A monoclonal antibody (mAb) is made by cloning a specific WBC or unique parent cell. Monoclonal antibodies have monovalent affinity, which means they bind to a specific molecular region or part of an antigen known as an epitope or antigenic determinant. Polyclonal antibodies bind to different epitopes produced by various antibody cell lineages. There are five higher animal types of immunoglobulins: IgG, IgM, IgA, IgE, and IgD. IgG is the most prevalent of all. Each IgG molecule consists of four polypeptide chains, including two heavy chains of 50 kDa and two light chains of 25 kDa, held together by four disulfide bridges.
FutureWise Market Research has published a report that provides an insightful analysis of Antibody Drug Conjugate Market trends affecting overall market growth.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Antibody-Drug-Conjugate/10050
Antibody Drug Conjugate Market Segmentation:
By Type
- Monoclonal Antibodies
- Linker
- Drug/Toxin
- Others
By Application
- Leukemia
- Acute Myeloid Leukemia (AML)
- Chronic Myeloid Leukemia (CML)
- Acute Lymphocytic Leukemia (ALL)
- Chronic Lymphocytic Leukemia (CLL)
- Prostate Cancer
- Kidney Cancer
- Pancreas Cancer
- Ovary Cancer
- Glioblastoma
- Lung Cancer
- Colon Cancer
- Breast Cancer
- Skin Cancer
- Solid Tumors
- Multiple Myeloma
- Lymphoma
By Product
- Adcetris
- Kadcyla
- Others
By Technology
- ImmunoGen Technology
- Seattle Genetics Technology
- Immunomedics Technology
- Others
By End User
- Hospitals
- Specialized Cancer Centers
- Academic Research Institutes
- Biopharmaceutical Companies
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Antibody Drug Conjugate Market:
- Seattle Genetics
- ImmunoGen, Inc.
- Roche Holding AG
- Genentech
- Concortis Biotherapeutics
- AGENSYS, INC.
- Antikor
- Immunomedics
- Pfizer Inc.
- Celldex Therapeutics
- Millennium Pharmaceuticals
- AbbVie Inc.
- Bayer HealthCare
- Astellas Pharma/Agensys
- Progenics Pharmaceuticals
- Mersana Therapeutics
- Synthon
- Heidelberg Pharma
- Oxford BioTherapeutics
Buy now the latest version of this report:
https://www.futurewiseresearch.com/checkout.aspx?ReportId=10050license=single
**Objectives of this Study: **
- To provide a comprehensive analysis of the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Related market:
Some of the other related markets that you might be interested in are listed as below:
Polymer Drug Conjugates Market
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
FutureWise Research
Contact Person: Vinay Thaploo.
Email: sales@futurewiseresearch.com
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com
